Targets › TXNRD1
8 programs from 8 companies in 9 trials: 6 Phase 2, 2 Phase 1, 1 Phase 3; Oncology, Hematology, Other; next expected readout Feb 2027.
Reduces disulfide protein thioredoxin (Trx) to its dithiol-containing form. Homodimeric flavoprotein involved in the regulation of cellular redox reactions, growth and differentiation. (UniProt, Q16881)
Open in Phaseline: the race on TXNRD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Children's Oncology Group | Arsenic Trioxide Thioredoxin reductase 1 inhibitor | TXNRD1 | Phase 3 | Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | Jun 2029 |
| The University of Hong Kong | Arsenic Trioxide Thioredoxin reductase 1 inhibitor | TXNRD1 | Phase 2 | Acute Myeloid Leukemia | Feb 2027 |
| Associazione Italiana Ematologia Oncologia Pediatrica | Arsenic Trioxide Thioredoxin reductase 1 inhibitor | TXNRD1 | Phase 2 | Acute Promyelocytic Leukemia | Oct 2027 |
| M.D. Anderson Cancer Center | Arsenic Trioxide Thioredoxin reductase 1 inhibitor | TXNRD1 | Phase 2 | Acute Promyelocytic Leukemia With PML-RARA | Dec 2027 |
| Yang Li | Arsenic Trioxide Thioredoxin reductase 1 inhibitor | TXNRD1 | Phase 2 | Neuroblastoma; Pediatric Cancer | Dec 2028 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Arsenic trioxide Thioredoxin reductase 1 inhibitor | TXNRD1 | Phase 2 | Neuroblastoma | May 2031 |
| Groupe Francophone des Myelodysplasies | Arsenic Trioxide Thioredoxin reductase 1 inhibitor | TXNRD1 | Phase 1 | Low-risk Myelodysplastic Syndromes | Jul 2027 |
| Xing Xie | Arsenic trioxide Thioredoxin reductase 1 inhibitor | TXNRD1 | Phase 1 | Efficacy and Safety | – |
Neuroblastoma (2) Pediatric Cancer (1) Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA (1) Acute Promyelocytic Leukemia With PML-RARA (1) Acute Myeloid Leukemia (1) Low-risk Myelodysplastic Syndromes (1) Acute Promyelocytic Leukemia (1) Efficacy and Safety (1)
small molecule (6), mixed (2)
Yang Li (1) Children's Oncology Group (1) M.D. Anderson Cancer Center (1) The University of Hong Kong (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Groupe Francophone des Myelodysplasies (1) Associazione Italiana Ematologia Oncologia Pediatrica (1) Xing Xie (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.